2nd Annual Protein Degradation for CNS Summit

The Protein Degradation for CNS Summit returns to Boston for its 2nd year running. With this ever-progressing field in neurodegenerative disease drug development, the design of protein degradation therapies has gained huge amounts of momentum. With the first patient dosed by Arvinas, the movement towards clinic has rapidly changed the focus of the field towards translating towards Phase I trials.

Be a part of the future of protein degradation for CNS diseases by keeping your knowledge up-to-date. Hear the latest findings in degrader design, target identification, mechanism selection and PKPD considerations at this industry-leading conference, with expert speakers from Arvinas, Biogen and Monte Rosa Therapeutics.

URLs:
Website: https://go.evvnt.com/2695554-0?pid=176
Tickets: https://go.evvnt.com/2695554-2?pid=176
Brochure: https://go.evvnt.com/2695554-3?pid=176

Time: 9:00 AM - 5:00 PM

Prices:
Drug Developer Pricing - Conference + Pre-Conference Workshop Day: USD 3497.00,
Drug Developer Pricing - Conference Only: USD 2599.00,
Solution-Provider Pricing - Conference + Pre-Conference Workshop Day: USD 5097.00,
Solution-Provider Pricing - Conference Only: USD 3699.00,
Academic Pricing - Conference + Pre-Conference Workshop Day: USD 2897.00,
Academic Pricing - Conference Only : USD 3699.00

Speakers: Beth Hoffman, Chief Executive Officer, Origami Therapeutics, Inc., Changhoon Ji, CTO and Executive Director, AUTOTAC Bio, Christopher Hickey, Associate Director, Arvinas, Inc., Emiliano Biasini, Co-Founder (Sibylla,) and Associate Professor Centre for Integrative Biology (Cibio), University of Trento, Jennifer Johnston, CEO, NysnoBio, Laura Silvian, SVP Physical Biochemistry, Biogen, Lili Zhang, SVP, Head of Preclinical Development, Aprinoia Therapeutics Inc., Magnus Walter, Senior Vice President Drug Discovery, Monte Rosa Therapeutics, Marianthi Papakosta, Director, Neuroscience Biology Research, Neurocrine Biosciences, Michal Walczak, Chief Scientific Officer and Co-founder, Captor Therapeutics, Mikolaj Slabicki, Cancer Program Group Leader and Postdoctoral Research Fellow, The Broad Institute of MIT and Harvard, Patrick Wen, Director, Center For Neuro-Oncology, Dana-Farber Cancer Institute, Pranam Chatterjee, Assistant Professor of Biomedical Engineering and Co-Founder (UbiquitX), Duke University, Ram Krishnan, Head of Neurodegenerative Disease Cluster, Sanofi, Simon Glerup, Chief Scientific Officer, Draupnir Bio Aps, Will Farnaby, Principal Investigator, University of Dundee